Cargando…
Adjunctive Probio-X Treatment Enhances the Therapeutic Effect of a Conventional Drug in Managing Type 2 Diabetes Mellitus by Promoting Short-Chain Fatty Acid-Producing Bacteria and Bile Acid Pathways
Metformin is a common drug for the management of type 2 diabetes mellitus; however, it causes various adverse gastrointestinal effects, especially after prolonged treatment. It is thus of interest to identify an adjuvant treatment that synergizes with the efficacy of metformin while mitigating its a...
Autores principales: | Chen, Ye, Shen, Xin, Ma, Teng, Yu, Xia, Kwok, Lai-Yu, Li, Yalin, Sun, Zhihong, Li, Dongmei, Zhang, Heping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948714/ https://www.ncbi.nlm.nih.gov/pubmed/36688679 http://dx.doi.org/10.1128/msystems.01300-22 |
Ejemplares similares
-
Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota
por: Gao, Guangqi, et al.
Publicado: (2021) -
Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes
por: Sun, Baoqing, et al.
Publicado: (2022) -
Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome
por: Zhang, Weiqin, et al.
Publicado: (2022) -
Change in the Gut Microbiome and Immunity by Lacticaseibacillus
rhamnosus Probio-M9
por: Zhang, Meng, et al.
Publicado: (2023) -
Lacticaseibacillus rhamnosus Probio-M9 extends the lifespan of Caenorhabditis elegans
por: Zhang, Juntao, et al.
Publicado: (2022)